Incyte Corporation (INCY) : Mariner Investment Group scooped up 12,400 additional shares in Incyte Corporation during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 3, 2016. The investment management firm now holds a total of 44,300 shares of Incyte Corporation which is valued at $4,022,883.Incyte Corporation makes up approximately 1.31% of Mariner Investment Group’s portfolio.
Other Hedge Funds, Including , Reilly Financial Advisors added INCY to its portfolio by purchasing 295 company shares during the most recent quarter which is valued at $26,789.Boston Advisors reduced its stake in INCY by selling 1,100 shares or 25.58% in the most recent quarter. The Hedge Fund company now holds 3,200 shares of INCY which is valued at $283,904. Incyte Corporation makes up approx 0.01% of Boston Advisors’s portfolio.Cornerstone Advisors boosted its stake in INCY in the latest quarter, The investment management firm added 110 additional shares and now holds a total of 552 shares of Incyte Corporation which is valued at $48,973. Incyte Corporation makes up approx 0.05% of Cornerstone Advisors’s portfolio.Quotient Investors reduced its stake in INCY by selling 43,303 shares or 75.44% in the most recent quarter. The Hedge Fund company now holds 14,100 shares of INCY which is valued at $1,164,096. Incyte Corporation makes up approx 0.53% of Quotient Investors’s portfolio.
Incyte Corporation closed down -2.8 points or -3.08% at $88.04 with 10,24,007 shares getting traded on Monday. Post opening the session at $90.68, the shares hit an intraday low of $87.9001 and an intraday high of $91.599 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
On the company’s financial health, Incyte Corporation reported $0.18 EPS for the quarter, beating the analyst consensus estimate by $ 0.20 according to the earnings call on Aug 9, 2016. Analyst had a consensus of $-0.02. The company had revenue of $246.30 million for the quarter, compared to analysts expectations of $232.33 million. The company’s revenue was up 51.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.05 EPS.
Many Wall Street Analysts have commented on Incyte Corporation. Company shares were Reiterated by Barclays on Aug 10, 2016 to “Overweight”, Firm has raised the Price Target to $ 100 from a previous price target of $85 .Company shares were Reiterated by Leerink Partners on Aug 10, 2016 to “Outperform”, Firm has raised the Price Target to $ 95 from a previous price target of $85 .Incyte Corporation was Initiated by SunTrust to “Buy” on Aug 5, 2016.
Incyte Corporation is a biopharmaceutical company focused on the discovery development and commercialization of small molecule drugs to treat serious unmet medical needs. The Company’s compound JAKAFI (ruxolitinib) also known as INCB18424 and INC424 is an oral Janus associated kinase (JAK) inhibitor used for the treatment for patients with intermediate or highrisk myelofibrosis (MF) including primary MF postpolycythemia vera MF and postessential thrombocythemia MF. The Company has a second oral JAK1 and JAK2 inhibitor LY3009104 (INCB28050) which is subject to a collaboration agreement with Eli Lilly and Company in which Lilly received development and commercialization rights f